Article
Author: Yalçın, Şuayip ; Tural, Deniz ; Artaç, Mehmet ; Cicin, İrfan ; Ökten, İlker Nihat ; Yildirim, Mahmut Emre ; Arslan, Çağatay ; Alacacioglu, Ahmet ; Dane, Faysal ; Gumus, Mahmut ; Öven, Başak ; Bozkurt, Oktay ; Şendur, Mehmet Ali Nahit ; Karabulut, Bülent ; Çubukçu, Erdem ; Harputluoğlu, Hakan ; Geredeli, Çağlayan ; Ozcelik, Melike ; Çelik, Sinemis ; Tanrikulu, Eda ; Türk, Hacı Mehmet ; Açıkgöz, Özgür ; Karadurmuş, Nuri ; Sakin, Abdullah ; Kefeli, Umut ; Karaca, Mustafa ; Çil, Timucin ; Urakçı, Zuhat ; Bilir, Cemil
Backgrounds and Objectives:Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311).
Materials and Methods:In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups.
Results:
A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively (
p
= 0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively (
p
= 0.848).
Conclusion:According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments.